OND.F Oncopeptides AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.1555 EUR
Close of Nov 13, 2026
0.1148 0.5000
Market cap
EUR 67.1M
P/E
-
P/B
29.92x
ROE
-697.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is OND.F undervalued?

Graham number

The Graham number of Oncopeptides AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oncopeptides AB (publ) fundamental analysis

No fundamental analysis for Oncopeptides AB (publ) yet.

Oncopeptides AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oncopeptides AB (publ)

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic…

Full company profile